Výsledky vyhledávání - "Josep, Grinyo"

Akademický článek

Acute Kidney Injury Following Chimeric Antigen Receptor T-Cell Therapy for B-Cell Lymphoma in a Kidney Transplant Recipient

Autor: Edoardo Melilli, Alberto Mussetti, Gabriela Sanz Linares, Marco Ruella, Charette La Salette, Alexandre Savchenko, Maria del Rosario Taco, Nuria Montero, Josep Grinyo, Alex Fava, Montse Gomà, Maria Meneghini, Anna Manonelles, Josepmaria Cruzado, Ana Sureda, Oriol Bestard

Publikováno v: Kidney Medicine, Vol 3, Iss 4, Pp 665-668 (2021)

Anti-CD19 chimeric antigen receptor (CAR) T-cell therapy is a newer and effective therapeutic option approved for patients with relapsed/refractory acute lymphoblastic leukemia and diffuse large B-cell lymphoma. Acute kidney injury is a complication

Externí odkaz: https://doaj.org/article/944abe382098468d84ef6dc601ac3025

Zobrazit plný text záznamu

Akademický článek

On the clinical relevance of using complete high-resolution HLA typing for an accurate interpretation of posttransplant immune-mediated graft outcomes

Publikováno v: Frontiers in Immunology, Vol 13 (2022)

Complete and high-resolution (HR) HLA typing improves the accurate assessment of donor–recipient compatibility and pre-transplant donor-specific antibodies (DSA). However, the value of this information to identify de novo immune-mediated graft even

Externí odkaz: https://doaj.org/article/7f5cf2b30d89419c885c1cfa441762ca

Zobrazit plný text záznamu

Improvement in renal function in kidney transplant recipients switched from cyclosporine or tacrolimus to belatacept: 2-year results from the long-term extension of a phase II study

Autor: Josep, Grinyo, Josefina, Alberu, Fabiana L C, Contieri, Roberto C, Manfro, Guillermo, Mondragon, Georgy, Nainan, Maria del C, Rial, Steven, Steinberg, Flavio, Vincenti, Yuping, Dong, Dolca, Thomas, Nassim, Kamar

Publikováno v: Transplant international : official journal of the European Society for Organ Transplantation. 25(10)

Kidney transplant recipients who switched from a calcineurin inhibitor (CNI) to belatacept demonstrated higher calculated glomerular filtration rates (cGFRs) at 1 year in a Phase II study. This report addresses whether improvement was sustained at 2

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::bf08c65f06798ccf1d0714cc1b9dce36
https://pubmed.ncbi.nlm.nih.gov/22816557

Zobrazit plný text záznamu

FTY720 - a novel immunomodulator - Efficacy and safety results from the first phase 2a study in de novo renal transplantation

Autor: Barry D. Kahan, Shamkant Mulgaonkar, Søren Madsen, Helio Tedesco-Silva, Josep Grinyo Boira, Willem Weimar, Georges Mourad, Björn Nashan, Bernard Charpentier, Yves Vanrenterghem, Pascale Pellet

Publikováno v: Transplantation, 77(12), 1826-1833. Lippincott Williams & Wilkins
Madsen, S, Tedesco-Silver, H, Mourad, G, Kahan, B D, Boira, J G, Weimar, W, Mulgaonkar, S, Nashan, B, Charpentier, B, Pellet, P & Vanrenterghem, Y 2005, ' FTY720, a novel immunomodulator: Efficacy and safety results from the first phase 2A study in de novo renal transplantation. ' Transplantation, vol. 79, pp. 1553-1560 .
Tedesco-Silva, H, Mourad, G, Kahan, B D, Boira, J G, Weimar, W, Mulgan, S, Nashan, B, Madsen, S, Charpentier, B, Pellet, P & Vanrenterghem, Y 2004, ' FTY-720, a novel immunomodulator: efficacy and safety results from the first phase 2a study in de novo renal transplantation ', Transplantation, no. 77, pp. 1826-1833 .

BACKGROUND FTY720 is the first of a new drug class: sphingosine-1-phosphate receptor agonist. Its effect relates to the modulation of lymphocytes trafficking from blood and peripheral tissues to lymph nodes. This is the first study to evaluate the ef

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3207b1d2c45943339101e6f1bca114bb
https://pure.eur.nl/en/publications/91a5edf3-4ffa-49a2-8dc0-73986ff05834